BioRestorative Therapies

BioRestorative Therapies Interest Coverage

The Interest Coverage Ratio of BioRestorative Therapies (BRTX) as of Nov 4, 2026 is -18.76. In the previous year, Interest Coverage Ratio was -3.35 — a change of 460.67% (lower).

Interest Coverage

-18.76

YoY

460.67%

Last updated:

Interest Coverage Ratio of BioRestorative Therapies is 2024 -18.76 . Interest Coverage Ratio of BioRestorative Therapies was 2023 -3.35 . It decreases by 460.67% lower compared to the previous year.

The BioRestorative Therapies Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2017
-8.55 USD
Jan 1, 2018
-2.22 USD
Jan 1, 2019
-1.94 USD
Jan 1, 2020
-0.73 USD
Jan 1, 2021
-14.45 USD
Jan 1, 2022
-1,886.35 USD
Jan 1, 2023
-3.35 USD
Jan 1, 2024
-18.76 USD
The BioRestorative Therapies Interest Coverage history
YEARInterest CoverageYoY
-18.76+460.67%
-3.35-99.82%
-1,886.35+12,949.93%
-14.45+1,885.39%
-0.73-62.44%
-1.94-12.56%
-2.22-74.06%
-8.55-16.71%
-10.26-14.15%
-11.95+82.08%
-6.56—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioRestorative Therapies Stock analysis

What does BioRestorative Therapies do? BioRestorative Therapies Inc generates revenue through the development and commercialization of cell-based therapeutic products. The company focuses on two primary programs: the Disc/Spine Program (brtxDISC) and the Metabolic Program (ThermoStem). Its lead product, BRTX-100, is a cell therapy formulated from autologous cultured mesenchymal stem cells derived from patients' bone marrow, designed for non-surgical treatment of lumbosacral disc disorders. The company also develops ThermoStem, a therapy using brown adipose-derived stem cells to create brown adipose tissue for metabolic conditions like obesity and diabetes. BioRestorative Therapies targets medical professionals and healthcare institutions seeking innovative cell therapies for chronic conditions, with its products in development stages focused on specific therapeutic applications. The company’s revenue model relies on the future commercialization of BRTX-100 and ThermoStem, with no current sales reported. Its proprietary production process for BRTX-100 involves collecting bone marrow, isolating and culturing stem cells, and cryopreserving them. ThermoStem’s development targets metabolic disorders, leveraging the company’s expertise in cell and tissue protocols. BioRestorative Therapies Inc operates as a life sciences firm specializing in adult stem cell therapies, with its products positioned for potential market entry in the biotechnology sector. BioRestorative Therapies Inc’s business strategy centers on advancing its pipeline of cell-based therapies, including BRTX-100 for disc disorders and ThermoStem for metabolic conditions. The company’s focus on proprietary technology and cell culture methods differentiates its approach within the biotechnology industry. While currently in development, its products aim to address unmet medical needs, targeting healthcare providers and patients with chronic conditions requiring non-surgical interventions. BioRestorative Therapies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioRestorative Therapies stock

Interest Coverage Ratio of BioRestorative Therapies is -18.76 in 2024.

Interest Coverage Ratio of BioRestorative Therapies changed from -3.35 to -18.76, representing a 460.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio BioRestorative Therapies since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's BioRestorative Therapies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — BioRestorative Therapies

All Key Metrics — BioRestorative Therapies